Nexium (Esomeprazole Magnesium Trihydrate)

Esomeprazole magnesium trihydrate, the active ingredient in Nexium, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid production and is indicated for conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Nexium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexium, a proton pump inhibitor, is employed in the management of several acid‑related gastrointestinal conditions.

- Gastroesophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining higher gastric pH. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions. - NSAID‑induced gastric ulcer: protects gastric mucosa and facilitates ulcer healing. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion in this rare endocrine disorder. - Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotic regimens by reducing gastric acidity.

Adverse reactions to Nexium may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often reported during early therapy. - Diarrhea: loose stools occurring in a subset of patients. - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of unease or urge to vomit. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis associated with altered gut flora. - Severe allergic reactions (anaphylaxis): rapid onset of rash, swelling, and breathing difficulty. - Hypomagnesemia: low magnesium levels with prolonged use. - Stevens‑Johnson syndrome: rare, life‑threatening skin reaction.

Before initiating Nexium, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess renal function: dose adjustment may be required in severe renal impairment. - Monitor for osteoporosis: long‑term use may affect bone mineral density. - Avoid in patients with known hypersensitivity to esomeprazole or other PPIs. - Use with caution in hepatic impairment: consider dose reduction. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Nexium can affect the pharmacokinetics of several co‑administered drugs; interaction severity varies.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect; avoid concurrent use. - Atazanavir: decreased absorption of atazanavir; avoid.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Digoxin: increased serum levels; monitor for toxicity. - Methotrexate: reduced renal clearance; monitor levels.